Kava Composition Purification and Kratom Micronization for Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing kava and kratom compositions are associated with hepatotoxicity due to the presence of flavokavain A and flavokavain B, and kratom compositions lack stability in solution, limiting their nutraceutical and pharmaceutical benefits.
Innovation Solution
Development of kava and kratom compositions substantially free of flavokavain A and flavokavain B, and kratom compositions with improved colloidal stability through micronization and irradiation, respectively, to enhance their safety and effectiveness.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If kava compositions containing flavokavain A and flavokavain B are used, then anesthetic and anti-anxiogenic properties are achieved, but hepatotoxicity occurs
Solution Approach 1:
The patent applies extraction by removing the harmful components (flavokavain A and flavokavain B) from the kava composition while retaining the beneficial kavalactones. This is achieved through selective extraction processes that separate desired compounds from toxic compounds, resolving the contradiction between maintaining therapeutic effects and eliminating hepatotoxicity.
Solution Approach 2:
The patent changes the compositional parameters of kava extracts by controlling the extraction process to achieve specific ratios of kavalactones to flavokavains. By adjusting extraction parameters such as solvent composition, temperature, and pressure, the patent produces compositions with reduced flavokavain content while maintaining effective kavalactone levels, thereby reducing hepatotoxicity while preserving therapeutic benefits.
2Reliability
If kratom compositions are prepared in solution, then bioavailability is improved, but colloidal stability deteriorates
Solution Approach 1:
The patent applies preliminary action by pre-processing kratom material through micronization and irradiation before solution preparation. Micronization reduces particle size to enhance dissolution and colloidal stability, while irradiation (such as gamma irradiation) sterilizes and stabilizes the material. These preliminary treatments ensure that when the kratom is subsequently prepared in solution, it maintains superior colloidal stability and bioavailability.
Solution Approach 2:
The patent changes physical parameters of the kratom composition through micronization (reducing particle size to micrometer scale) and controls solution parameters such as pH, ionic strength, and surfactant concentration. These parameter changes optimize the colloidal properties of kratom in solution, preventing aggregation and sedimentation while maintaining bioavailability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The novel compositions significantly reduce hepatotoxicity risks and improve stability, enabling effective treatment of neurodivergent conditions and enhancement of cognitive abilities, mood, relaxation, and energy levels.
Implementation Method 1
kratom compositions with improved colloidal stability through micronization and irradiation
Data Source
AI summary
Kava and kratom compositions are described herein along with the methods of producing the same. The description contained herein describes methods for making a purified kava composition that is free or substantially free of flavokavain A and flavokavain B. In some embodiments, the kava composition is formulated as a ready-to-drink beverage. Certain compositions comprise a combination of a kava composition and a kratom composition made in accordance with the methods described herein.